Brazil's health regulatory agency Anvisa created a working group on June 16, 2026 [1], to evaluate the safety of the Butantan-DV dengue vaccine.
The move comes as the government seeks to determine if a causal link exists between the vaccine and reported deaths and serious adverse events. Because the Butantan-DV was approved as Brazil's first single-dose dengue vaccine, any safety concerns could impact the broader national immunization strategy.
The working group will deepen the technical evaluation of the vaccine's safety profile [1]. This process follows reports of severe reactions and deaths among recipients of the shot. Anvisa is tasked with analyzing these events to ensure public health safety and determine if the vaccine's benefits continue to outweigh its risks [1].
While the agency has initiated this investigation, the Ministry of Health said that no causal link between the vaccine and the reported deaths has been proven. The investigation aims to provide a definitive scientific assessment of these occurrences [1].
The Butantan Institute developed the vaccine to provide a streamlined, single-dose alternative for dengue prevention. The current investigation by Anvisa is a regulatory response to post-market surveillance data, a standard part of monitoring new medical products once they reach the general population [1].
Anvisa officials are now reviewing the clinical data and reported adverse events to decide if any changes to the vaccine's administration or approval status are necessary. The agency has not yet issued a suspension of the vaccine's use, but the formation of the specialized group indicates a heightened level of scrutiny regarding the Butantan-DV safety data [1].
“Anvisa created a working group to evaluate the safety of the Butantan-DV dengue vaccine.”
The formation of this working group reflects the tension between rapid vaccine deployment and rigorous post-market safety monitoring. If Anvisa finds a causal link between the vaccine and severe adverse events, it could lead to revised dosing guidelines, restricted eligibility, or a full recall of the single-dose product, potentially slowing Brazil's efforts to combat dengue outbreaks.
